Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease

Expert Review of Respiratory Medicine

Volumn 9, Issue 1, 2015, Pages 23-33

  Riario Sforza, Gian Galeazzo ^a   Ridolo, Erminia ^b   Riario Sforza, Edoardo ^a   Incorvaia, Cristoforo ^a  

^a ICP Hospital   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

COPD; efficacy; glycopyrronium bromide; muscarinic antagonists; safety; Treatment

Indexed keywords

ACLIDINIUM BROMIDE; DAROTROPIUM BROMIDE; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL; IPRATROPIUM BROMIDE; OLODATEROL; OLODATEROL PLUS TIOTROPIUM BROMIDE; PLACEBO; SALBUTAMOL; TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; VILANTEROL; BRONCHODILATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSPNEA; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HEALTH STATUS; HUMAN; MAINTENANCE THERAPY; METALLIC TASTE; MONOTHERAPY; REVIEW; TACHYCARDIA; TREMOR; URINARY TRACT INFECTION; URINE RETENTION; XEROSTOMIA; CONVALESCENCE; DRUG ADMINISTRATION; DRUG EFFECTS; LUNG; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; GLYCOPYRROLATE; HUMANS; LUNG; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84920973729     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2015.996133     Document Type: Review

References (50)

1. Vestbo J, Hurd SS, AgustÀG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65
2. Rabe KF, Hurd S, Anzueto A, et al. Review Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532-55
3. Yohannes AM, Willgoss TG, Vestbo J. Review Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Respir Care 2011;56(4):477-87
4. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010;11:149-63
5. Keating GM. Tiotropium bromide inhalation power: a review of its use in the management of chronic obstructive pulmonary disease. Drugs 2012;72:273-300
6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2014. Available from: www.goldcopd.org
7. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res 2013;14(1):49
8. Maclay JD, Rabinovich RA, MacNee W. Update in chronic obstructive pulmonary disease 2008. Am J Respir Crit Care Med 2009;179(7):533-41
9. Rossi A, Khirani S, Cazzola M. Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety. Int J Chron Obstruct Pulmon Dis 2008;3(4):521-9
10. D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011;12:156-68
11. Kerwin E, Hebert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: the GLOW2 study. Eur Resp J 2012;40(5): 1106-14
12. Beeh K, Drollmann A, Di Scala L, Smith R. Once-daily NVA237 improves exercise endurance from first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012;7:503-13
13. Novartis Europharm Ltd. Seebri-Breezhaler-(glycopyrronium bromide) powder for inhalation: EU summary of product characteristics. 2012
14. Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005;2(1):99-103
15. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005;2(1): 75-9
16. Sekiya M et al. Safety and efficacy of NVA237 once daily in Japanese patients: the GLOW4 trial. ERS abstract 853970; Session 245; Hall A-7; Mon 3 Sep
17. Chapman KR1, Beeh KM, Beier J, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily longacting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med 2014;14:4
18. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. Available from: www.goldcopd.org/
19. Beeh KM, Beier J, Donohue JF. Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Respir Res 2012;13:52
20. Vincken W, Aumann J, Chen H, et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis 2014;9:215-28
21. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: www.goldcopd.org/
22. van Noord JA, Aumann JL, Janssens E, et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med 2010;104(7): 995-1004
23. Vincken W. An update of bronchodilator treatment of chronic obstructive pulmonary disease (COPD). Ann Respir Med 2010;1: 1-16
24. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono-and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008; 102(11):1511-20
25. Mahler DA, D'Urzo A, Bateman ED, et al. INTRUST-1 and INTRUST-2 study investigators. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012; 67(9):781-8
26. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42(6):1484-94
27. Kume H, Imbe S, Iwanaga T, Tohda Y. Synergistic effects between glycopyrronium bromide and indacaterol on a muscarinic agonist-induced contraction in airway smooth muscle. European Respiratory Society Annual Congress, Vienna, Austria, 2012;888, abstract
28. D'Urzo A, Vogelmeier C. Future of chronic obstructive disease management. Expert Rev Respir Med 2012;6:285-99
29. Dahl R, Jadayel D, Alagappan VKT, et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis 2013;8:501-8
30. Mahler DA, Decramer M, D'Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J 2014;43(6):1599-609
31. Beeh KM, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med 2014;108(4):584-92
32. Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 2013; 107(10):1558-67
33. Vogelmeier C, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone in patients with COPD (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013;1(1):51-60
34. A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149 (LANTERN). NCT01709903. Available from: http://clinicaltrials.gov/ct2/show/NCT01709903
35. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of Chronic Obstructive Pulmonary Disease Exacerbations with the Dual Bronchodilator QVA149 Compared with Glycopyrronium and Tiotropium (SPARK): a Randomized, Double-blind, Parallel-group Study. Lancet Respir Med 2013;1(3):199-209
36. Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD) (ARISE). Available from: www.clinicaltrials.gov/ct2/show/NCT01285492?term=%28ARISE% 29&rank=4
37. A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) With Salmeterol/Futicasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD (FLAME). Available from: www.clinicaltrials.gov/ct2/show/NCT01782326?term=qva149 +salmeterol%2Ffluticasone&rank=1
38. Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation (GLISTEN). [Online]. Available from: www.clinicaltrials.gov/ct2/show/NCT01610037?term=GLISTEN&rank=1
39. Verkindre C, Fukuchi Y, Fle-male A, et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010;104(10):1482-9
40. Vogelmeier C, Verkindre C, Cheung D, et al. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther 2010;23(5):438-44
41. Fogarty C, Hattersley H, Di Scala L, Drollmann A. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2011;105(3):337-42
42. Rodrigo GJ, Plaza V. Efficacy and Safety of a Fixed-Dose Combination of Indacaterol and Glycopyrronium for the Treatment of COPD: a Systematic Review. Chest 2014; 146(2):309-17
43. Wedzicha JA, Dahl R, Buhl R, et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med 2014. [Epub ahead of Print]
44. Tashkin DP, Celli B, Senn S, et al. the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359(15):1543-54
45. Incorvaia C, Russo A, Foresi A, et al. Effects of pulmonary rehabilitation on lung function in chronic obstructive pulmonary disease: the FIRST study. Eur J Phys Rehabil Med 2014;50(4):419-26
46. European Medicine Agency. European public assessment report: Seebri Breezhaler. 2012
47. Sykes DA, Dowling MR, Leighton-Davies J, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp 2012;342(2): 520-8
48. Ismaila A, Corriveau D, Vaillancourt J, et al. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary disease patients. Curr Med Res Opin 2014; 30(7):1427-36
49. Kelly E. Umeclinidium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol 2014;7(4): 403-13
50. Shen LL, Liu YN, Shen HJ, et al. Inhalation of glycopirronium inhibits cigarette smoke-induced acute kung inflammation in a murine model of COPD. Int Immunopharmacol 2014;18(2):358-64